Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Science (American Association for the Advancement of Science) 2020-08, Vol.369 (6504), p.718-724
Hauptverfasser: Hadjadj, Jérôme, Yatim, Nader, Barnabei, Laura, Corneau, Aurélien, Boussier, Jeremy, Smith, Nikaïa, Péré, Hélène, Charbit, Bruno, Bondet, Vincent, Chenevier-Gobeaux, Camille, Breillat, Paul, Carlier, Nicolas, Gauzit, Rémy, Morbieu, Caroline, Pène, Frédéric, Marin, Nathalie, Roche, Nicolas, Szwebel, Tali-Anne, Merkling, Sarah H, Treluyer, Jean-Marc, Veyer, David, Mouthon, Luc, Blanc, Catherine, Tharaux, Pierre-Louis, Rozenberg, Flore, Fischer, Alain, Duffy, Darragh, Rieux-Laucat, Frédéric, Kernéis, Solen, Terrier, Benjamin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor-κB and characterized by increased tumor necrosis factor-α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.
ISSN:0036-8075
1095-9203
1095-9203
DOI:10.1126/science.abc6027